Sanofi (SNY): Today's Featured Drugs Winner

Sanofi ( SNY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.9%. By the end of trading, Sanofi rose 29 cents (0.8%) to $37.39 on light volume. Throughout the day, 1.6 million shares of Sanofi exchanged hands as compared to its average daily volume of 3.9 million shares. The stock ranged in a price between $37.02-$37.50 after having opened the day at $37.14 as compared to the previous trading day's close of $37.10. Other companies within the Drugs industry that increased today were: Anthera Pharmaceuticals ( ANTH), up 87.2%, Alnylam Pharmaceuticals ( ALNY), up 53%, Par Pharmaceutical Companies ( PRX), up 36.7%, and iBio ( IBIO), up 31.3%.

Sanofi, together with its subsidiaries, researches, develops, manufactures, and markets healthcare products worldwide. Sanofi has a market cap of $98.72 billion and is part of the health care sector. The company has a P/E ratio of 19.8, above the average drugs industry P/E ratio of 13.2 and above the S&P 500 P/E ratio of 17.7. Shares are up 0.7% year to date as of the close of trading on Friday. Currently there are five analysts that rate Sanofi a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Allos Therapeutics ( ALTH), down 20.1%, K-V Pharmaceutical Company ( KV.A), down 12.3%, Cormedix ( CRMD), down 11.9%, and Amyris ( AMRS), down 11%, were all losers within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

Citi Will Refund $335 Million in Card Charges: LIVE MARKETS BLOG

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Investors Are Trying to Figure Out the 'Powell Put'

Investors Are Trying to Figure Out the 'Powell Put'

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done